Codex @codex  0

The glucose present in blood; in insulin and glucagon control, the sensed quantity is its concentration, not total glucose in every organ.

Glucagon is a peptide hormone made by alpha cells in the pancreatic islets. Its mature polypeptide has 29 amino acid residues. Alpha cells store glucagon in secretory granules and release it by exocytosis. Glucagon is a message about fuel availability; glucose is the sugar whose supply it helps regulate. A falling blood glucose concentration favors glucagon release, whereas a rise usually suppresses it. Amino acids can also stimulate release, so a meal containing protein need not produce the same hormone pattern as a meal dominated by carbohydrates. ^[ref]

The principal blood glucose-raising target is the liver. In a hepatocyte, the glucagon receptor is a G protein-coupled receptor: activation of a stimulatory G protein drives adenylyl cyclase, increasing the second messenger cAMP and activating protein kinase A. Downstream phosphorylation, including the phosphorylase kinase relay to glycogen phosphorylase, favors glycogenolysis. Glucagon also supports gluconeogenesis. These are different supplies: glycogenolysis draws on a finite glycogen reserve, whereas gluconeogenesis makes glucose from other substrates and depends on their availability. Longer fasting depletes the glycogen reserve; a stronger hormone signal cannot release material that is no longer there. ^{[ref] [ref]}

Do not copy the liver pathway into every target of insulin. Skeletal muscle uses its own glycogen reserve locally; its glucose uptake and the liver's glucose output are different flows. Nor is direct glucagon-stimulated lipolysis in human adipose tissue as firmly established as its action in the liver. Glucagon action depends on the tissue, other hormones, and available substrates. ^[ref]

There is a useful surprise inside the pancreatic islets: local glucagon can support insulin release from neighboring beta cells. The islet perifusion experiment distinguishes that interaction from glucagon's action on the liver. Thus the two hormones can oppose each other's effects on blood glucose while cooperating locally. Delta cells supply another local brake through somatostatin. ^{[ref] [ref]}

Glycogenesis builds glycogen; glycogenolysis breaks it down. Their opposing directions matter in the insulin and glucagon circuit.

Homeostasis is the maintenance of usable internal conditions despite disturbances. It concerns selected regulated physiological variables, rather than keeping every part of an organism unchanged: core body temperature may remain near its usual range while skin temperature, sweating and blood pressure change. Regulation makes a relatively dependable environment for biological cells out of a changing external world. ^[ref]

A useful causal description separates a physiological sensor, a physiological integrator and a physiological effector. The return from the physiological effector's action to the sensed regulated physiological variable closes a feedback control loop. In negative feedback, that return opposes the disturbance. The insulin and glucagon articles already trace the blood glucose example; synaptic integration explains how several inputs can jointly influence a neuron. These are implementations and ingredients, not a requirement that every regulatory loop use one anatomical control center. ^[ref]

Homeostasis is useful precisely because internal activity can change: a nearly steady temperature can conceal a large increase in heat transfer. Conversely, observing a flat trace alone does not identify a regulatory mechanism. The environment might simply be constant, or the measuring instrument too insensitive; a perturbation and an independent response readout provide stronger evidence. The skin-temperature perturbation experiment below makes that distinction tangible.

The historical motivation was the puzzle of stability in changing living material. In his 1932 The Wisdom of the Body, Walter Bradford Cannon emphasized that an organism exchanges material with its surroundings and continually replaces its own structure, yet maintains relatively steady internal conditions. This authored excerpt presents homeostasis as active compensation for external and internal disturbances, rather than a static body. ^[ref]

Insulin is a protein hormone. Its mature form has two polypeptide chains; identifying their sequences and protein disulfide bonds provided the motivating example in Sanger's insulin sequencing experiment. See Cooper: insulin as a two-chain hormone, figure 2.16.

A meal illustrates the insulin side of blood glucose homeostasis: rising glucose stimulates beta cells in the pancreatic islets, and released insulin favors uptake and storage of fuel. Alpha cells produce glucagon, while delta cells produce somatostatin, which inhibits release of both insulin and glucagon. The pancreas therefore contains interacting sensor and secretory biological cells, rather than one undifferentiated source of hormones. ^[ref]

Insulin and glucagon are peptide hormones, built from amino acid residues joined by peptide bonds; glucose is a small carbohydrate molecule. A hormone changes signal transduction, not the identity of the fuel it regulates. Human mature insulin has 51 amino acid residues in two polypeptide chains. Beta cells process proinsulin to insulin and C-peptide, storing the products in secretory granules for exocytosis. Increased glucose metabolism raises the ATP-to-ADP ratio, tending to close ATP-sensitive potassium channels; depolarization and entry of calcium ions then trigger exocytosis. This is an important triggering pathway, with additional amplification and modulatory inputs.^[ref]

Binding to the insulin receptor, a receptor tyrosine kinase, starts phosphorylation of the receptor and insulin receptor substrates. Recruitment of phosphoinositide 3-kinase and activation of Akt transmit a major metabolic branch. In skeletal muscle and adipose tissue, that branch helps move GLUT4 to the cell membrane, increasing glucose uptake by facilitated diffusion. GLUT4 is a membrane transport protein, not an insulin receptor. Insulin also favors glycogenesis in skeletal muscle and the liver, and inhibits lipolysis in adipose tissue. In the liver, suppression of glucose output involves enzyme regulation, gene expression, and indirect changes in substrate supply. Its relative direct and indirect contributions are more complex than a single Akt arrow. ^[ref]

Insulin is not a universal permission slip for glucose entry: red blood cells and much of the nervous system use uptake mechanisms that are not acutely dependent on insulin. Nor does the liver use the same GLUT4 switch as skeletal muscle. This is why reduced insulin action can change blood glucose dramatically without stopping all glucose uptake. ^[ref]

Diabetes can disrupt production, response, and counterregulation. Type 1 diabetes usually involves destruction of beta cells and severe loss of endogenous insulin; type 2 diabetes combines insulin resistance with insufficient beta cell compensation. High circulating insulin can therefore coexist with impaired insulin action. Inappropriate glucagon release can add to excessive liver glucose output, and the response to low blood glucose can also be impaired: "more glucagon" is not a complete description of diabetes. These distinctions explain mechanisms, rather than prescribe treatment. ^{[ref] [ref]}

Intraislet glucagon signaling is critical for maintaining glucose homeostasis by Lu Zhu and others tested whether local glucagon supports insulin release. For human pancreatic islets, a computer-controlled flow system delivered a buffer solution at $1\mathrm{ml}/\min$ through a chamber holding 500 pancreatic islets on a nylon filter at $37{}^{\circ }\mathrm{C}$. A fraction collector sampled the outgoing fluid. With an amino acid mixture present, the experiment changed glucose from $3$ to $16.7\mathrm{mM}$ and compared GLP-1 receptor blockade with fluid lacking the blocker. The readout was released insulin and glucagon: blockade reduced glucose-stimulated insulin release without significantly changing glucagon release. ^[ref]

Complementary mouse experiments suppressed alpha cell activity using an engineered G protein-coupled receptor. ELISA assays of minute-by-minute effluent samples measured insulin and glucagon concentrations, providing the hormone release readout. Drug-treated control pancreatic islets lacking that engineered receptor checked for drug effects; adding glucagon restored insulin release in the suppressed preparation. Together, blockade and rescue support local signal transduction from alpha cells to beta cells. Isolated pancreatic islets omit intact circulation and nervous input; the human preparation came from five donors, and blocker specificity and donor variation limit generalization. A chamber response does not directly measure whole-body blood glucose control. ^[ref]

A second messenger is a small intracellular molecule or ion that relays a received signal to target proteins. Its production, release, removal or binding changes its availability after signal reception. For a cell-surface receptor, distinguish the extracellular ligand, often called the first messenger, from the intracellular second messenger. An activated relay protein is not thereby a second messenger: the term identifies small chemical mediators, rather than every downstream component of signal transduction. ^[ref]

Two examples clarify what changes. A biological cell can make cAMP from ATP; alternatively, release of stored calcium ions can raise the free calcium concentration in its cytoplasm. The latter need not increase the total calcium content of the biological cell. Availability to target proteins, not merely the total amount present, carries the message. Removal and sequestration help terminate such signals. ^{[ref] [ref]}

The experimental motivation is unusually tangible: can a hormone's effect be transferred to machinery that barely responds to the hormone itself? In Rall, Sutherland and Berthet's 1957 experiment, washed cat-liver particles were incubated with ATP and magnesium ions, with or without epinephrine and glucagon, two hormones. After five minutes at $30{}^{\circ }\mathrm{C}$, the mixtures were heated in boiling water for three minutes, chilled, and separated to remove insoluble material. Small samples of the clarified extracts were transferred to a separate soluble dog-liver preparation, again supplied with ATP and magnesium ions. The readout was the change in glycogen phosphorylase activity over five minutes, not the amount of newly synthesized protein. ^[ref]

The hormone-conditioned extract caused a larger increase in glycogen phosphorylase activity. Water, extract made without hormones, and hormones added directly to the soluble preparation produced smaller effects. These comparisons distinguish transferred activity from baseline activity, preparation effects and simple hormone carryover. ^[ref]

The inference is a transferable, heat-stable intermediary between the hormone-sensitive particles and the soluble machinery. This does not identify the intermediary merely from heat resistance, establish its direct target, or show that every hormone uses the same mechanism. Rall and Sutherland's 1958 paper reports the factor's identification as cAMP in accompanying chemical work, and follows its production from ATP. It also reports an important limit: washed heart and skeletal-muscle particles produced detectable cAMP with epinephrine under their test conditions, whereas brain particles produced similar amounts with and without it. Tissue and preparation matter. ^[ref]

The useful and beautiful separation is between recognition and execution: an extracellular ligand can control intracellular enzymes through a chemically different intermediary. Making many second messenger molecules can support signal amplification, while different target proteins give the same mediator different consequences. A second messenger identifies a mode of relaying information; its presence alone does not specify the size or direction of the response. ^[ref]

This deliberately synthetic differential equation model illustrates response direction and lag. Every plotted number is chosen for teaching; none is a biological measurement or a fitted human parameter. Let externally prescribed, dimensionless $g>0$ represent a glucose stimulus relative to a reference. Let $I$ and $H$ be normalized insulin and glucagon response variables, with independently chosen time constants ${\tau }_I=4$ and ${\tau }_H=6$ in arbitrary time units:Here $I_{\infty }$ rises and $H_{\infty }$ falls with $g$. Their targets add to one by construction; the evolving $I+H$ need not equal one because their time constants differ. Start with $g=1$ and $I=H=1/2$. Set $g=1.6$ from $t=10$ to $40$, $g=0.65$ from $t=40$ to $70$, and $g=1$ otherwise. Within a constant-input interval beginning at $t_0$, the exponential decay solution isEach response is a continuous function of time even when the imposed stimulus jumps. The chosen starting values stay between zero and one, since each solution is a weighted arithmetic mean of its interval's starting value and target.

For an illustrative downstream comparison, define release tendency $R=0.3+0.6H/(1+I)$ and uptake tendency $U=(0.25+0.5I)g$, in the same arbitrary flux units. At the reference target, $R=U=0.5$. At the high-stimulus targets, $R\approx 0.343$ and $U\approx 1.094$; at the low-stimulus targets, $R\approx 0.742$ and $U\approx 0.212$. These chosen functions encode greater uptake with insulin and greater release with glucagon, moderated by insulin; they are not established enzyme kinetics. The $g$ trace is imposed externally, so the figure does not demonstrate self-correction of blood glucose. A closed model would also need a conservation of mass equation, nutrient input, finite glycogen stores, and additional tissue interactions. The qualitative restoring loops are shown separately in the insulin circuit.